Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.
OBJECTIVE
Neoadjuvant chemotherapy followed by surgery is the standard of care for patients with gastro-oesophageal adenocarcinoma. Previously, we validated the utility of the tumour regression grade (TRG) as a histopathological marker of tumour downstaging in patients receiving platinum-based neoadjuvant chemotherapy. In this study we profiled key DNA repair and damage signalling factors and correlated them with clinicopathological outcomes, including TRG response.


RESULTS
Formalin-fixed human gastro-oesophageal cancers were constructed into tissue microarrays (TMAs). The first set consisted of 142 gastric/gastro-oesophageal cancer cases not exposed to neoadjuvant chemotherapy and the second set consisted of 103 gastric/gastro-oesophageal cancer cases exposed to preoperative platinum-based chemotherapy. Expressions of ERCC1, XPF, FANCD2, APE1 and p53 were investigated using immunohistochemistry. In patients who received neoadjuvant chemotherapy, favourable TRG response (TRG 1, 2 or 3) was associated with improvement in disease-specific survival (P=0.038). ERCC1 nuclear expression correlated with lack of histopathological response (TRG 4 or 5) to neoadjuvant chemotherapy (P=0.006) and was associated with poor disease-specific (P=0.020) and overall survival (P=0.040).


CONCLUSIONS
We provide evidence that tumour regression and ERCC1 nuclear protein expression evaluated by immunohistochemistry are promising predictive markers in gastro-oesophageal cancer patients receiving neoadjuvant platinum-based chemotherapy.
Fareed
K R
KR
Laboratory of Molecular Oncology, Academic Unit of Oncology, School of Molecular Medical Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.
Al-Attar
A
A
Soomro
I N
IN
Kaye
P V
PV
Patel
J
J
Lobo
D N
DN
Parsons
S L
SL
Madhusudan
S
S
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D054316:Biomarkers, Pharmacological / Q000032:analysis / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000378:metabolism; D002467:Cell Nucleus / Q000378:metabolism; D049109:Cell Proliferation; D004268:DNA-Binding Proteins / Q000378:metabolism*; D004720:Endonucleases / Q000378:metabolism*; D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017671:Platinum Compounds / Q000008:administration & dosage; D011379:Prognosis; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D016019:Survival Analysis; D046888:Tissue Array Analysis; D016896:Treatment Outcome; D047368:Tumor Burden / Q000502:physiology*
D054316:Biomarkers, Pharmacological; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D017671:Platinum Compounds; C071447:ERCC1 protein, human; D004720:Endonucleases
Ann Oncol. 2007 Mar;18(3):504-9
17322540
Cancer Biol Ther. 2006 Dec;5(12):1632-6
17106252
J Clin Oncol. 2001 Dec 1;19(23):4298-304
11731512
Trends Mol Med. 2005 Nov;11(11):503-11
16214418
Nat Rev Genet. 2007 Oct;8(10):735-48
17768402
Cancer Treat Rev. 2007 Oct;33(6):565-77
17707593
Br J Cancer. 2007 Jan 29;96(2):277-83
17211470
Ann Oncol. 2007 Mar;18(3):522-8
17229776
J Natl Cancer Inst. 1992 Oct 7;84(19):1512-7
1433335
Clin Cancer Res. 2005 Mar 15;11(6):2215-21
15788669
Oncogene. 2003 Oct 20;22(47):7265-79
14576837
Clin Cancer Res. 2004 Jun 1;10(11):3794-9
15173087
Anticancer Agents Med Chem. 2007 Jan;7(1):3-18
17266502
Chembiochem. 2005 Jul;6(7):1157-66
15934047
Exp Cell Res. 2006 Aug 15;312(14):2647-53
16859679
Cancer Treat Rev. 2005 Dec;31(8):603-17
16298073
Nat Rev Cancer. 2003 Jan;3(1):23-34
12509764
Mol Cell Biol. 2006 Dec;26(24):9377-86
17000754
Mol Cancer Ther. 2006 Dec;5(12):3153-61
17172419
Prog Nucleic Acid Res Mol Biol. 2005;79:183-235
16096029
Nat Med. 1998 Jul;4(7):844-7
9662379
J Clin Oncol. 2009 Oct 20;27(30):5062-7
19770374
Clin Cancer Res. 2002 Jul;8(7):2286-91
12114432
Blood. 2005 Jul 15;106(2):698-705
15802532
N Engl J Med. 2006 Sep 7;355(10):983-91
16957145
J Clin Invest. 1994 Aug;94(2):703-8
8040325
Int J Oncol. 2009 Nov;35(5):1069-79
19787261
N Engl J Med. 2008 Jan 3;358(1):36-46
18172173
Histopathology. 2009 Oct;55(4):399-406
19817890
N Engl J Med. 2006 Jul 6;355(1):11-20
16822992
Chest. 2005 Mar;127(3):978-83
15764785
Chem Rev. 2006 Feb;106(2):253-76
16464005
J Clin Oncol. 1998 Jan;16(1):309-16
9440758
Clin Cancer Res. 2005 Oct 15;11(20):7508-15
16243825
Cell Oncol. 2006;28(1-2):3-29
16675878
DNA Repair (Amst). 2005 Dec 8;4(12):1442-9
16199212
Carcinogenesis. 1998 Dec;19(12):2145-9
9886570
Lancet. 2002 May 18;359(9319):1727-33
12049861
Cancer. 1994 Jun 1;73(11):2680-6
8194005
Lung Cancer. 2009 Dec;66(3):298-304
19324449
Br J Cancer. 2010 Feb 16;102(4):704-9
20087352
Cancer Treat Rev. 2007 Feb;33(1):9-23
17084534